It is good to see that the management reaffirm 2018 sales. Hopefully, this time, they will perform to expectation, and not like last year where they missed their own forecast twice in a row.
I think sleep and neuro diagnostic is an emerging industry that will see increase demand from users. However, with any capital equipment, hospital and institution usually wait and wait until patients knock on their doors to pay for the service before committing to investment. So, i think it is a good idea to clear regulatory hurdles such as FDA or continue to earn reputation by selling to leading institutions like world-renowned Barrow Neurological Institute, to become the go-to supplier. Then, once everyone is buying, they will buy from CMP.
In terms of capital structures and strategy, I really hope CMP management really consider the option of spin-off of non-core division such as DWL or even start licensing certain technology to larger firms to leverage its intellectual property.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)